Hypermarcas (OTCMKTS:HYPMY) Shares Gap Down - Here's Why

Key Points

• Hypermarcas' stock price gapped down from a previous close of $4.37 to an opening price of $4.12, amid low trading volume of 272 shares.
• The company recently received a "strong-buy" rating from Scotiabank, contributing to an overall consensus rating of "Strong Buy" among analysts.
• Hypermarcas announced a significant dividend of $0.0345 per share, equating to a striking dividend yield of 281.0%, to be paid on January 8th.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $4.37, but opened at $4.12. Hypermarcas shares last traded at $4.12, with a volume of 272 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Scotiabank raised shares of Hypermarcas to a "strong-buy" rating in a research note on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, Hypermarcas presently has a consensus rating of "Strong Buy".

Hypermarcas Trading Down 5.7%

The business's 50 day simple moving average is $4.59 and its two-hundred day simple moving average is $4.11. The stock has a market cap of $2.61 billion, a P/E ratio of 19.62 and a beta of 0.86. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.63.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a net margin of 11.28% and a return on equity of 6.19%.

Hypermarcas Dividend Announcement

The business also recently announced a dividend, which will be paid on Friday, January 8th. Shareholders of record on Tuesday, July 1st will be paid a dividend of $0.0345 per share. This represents a dividend yield of 281.0%. The ex-dividend date of this dividend is Monday, June 30th. Hypermarcas's payout ratio is presently 57.14%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.